IMMUNOTERAPİ SONRASINDA ANAFİLAKSİ GELİŞEN BİR OLGU SUNUMU

Yıl 2003, Cilt: 17 Sayı: 2, 29 - 32, 01.10.2003

Suna Köse Canan Şule Turgut Özkan Karaman Dilek Tezcan Nevin Uzuner

Öz

Ümmunoterapi çocukluk yaş grubunda allerjik rinit ve bronşiyal astımlı seçilmiş hastalarda uygulanmaktadır. Allerjen immunoterapisinin en önemli riski sistemik anafilaktik reaksiyon gelişmesidir. Bu nedenle immunoterapi enjeksiyonları anafilaksi önlemleri alınarak deneyimli klinisyenler tarafından uygulanmalıdır. Bu konuya dikkat çekmek amacıyla Olea europaya karşı immunoterapi yapılan tedavinin 7. ayında immunoterapi enjeksiyonu sonrası anafilaksi gelişen 8 yaşında bir erkek hasta sunulmuştur.

Anahtar Kelimeler

İmmunoterapi, anafilaksi, Olea europae duyarlılığı

A CASE REPORT: ANAPHYLAXIS AFTER IMMUNOTHERAPY INJECTION

Öz

Immunotherapy can be used in selected patients in the childhood extrinsic asthma and allergic rhinitis. The major risk of allergen immunotherapy is the development of systemic anaphylactic reactions. Therefore, immunotherapy must be performed by experienced clinicians after taking preventive care for anaphylaxis. We present an 8 year old male patient who developed anaphylaxis against Olea europea immunotherapy in the seventh month of treatment to raise awareness of this subject.

Anahtar Kelimeler

Immunotherapy, anaphylaxis, Olea europa sensitivity

Kaynakça

• 1. Grammer LC. Principles of immunologic management of allergic diseases due to extrinsic antigens. In Paterson’s Allergic Disease. (Eds) Grammer LC, Greenberger PA. Lippincott Williams & Wilkins 2002 Philedelphia pp:183-94.
• 2 Reisman RE, Tronolone MJ. Immunotherapy. Immunotherapy: a practical review and guide. Immunology and Allergy Clin of North America 2000, 20: 469-78.
• 3. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. J Allergy Clin Immunol 1998, 102: 558-62.
• 4. Kemp SF. Adverse effects of allergen ›mmunotherapy. Immunotherapy: A Practical Review and Guide. Immunology and Allergy Clin of North America 2000, 20: 571-91.
• 5. Greineder DK. Risk management in allergen immunotherapy. J Allergy Clin Immunol. 1996, 98: 330-4.
• 6. Aas K, Belin L. Standardization of diagnostic work in allergy. Acta Allergologica 1972; 27: 439-68.
• 7. Rogola B.Risk and safety immunotherapy. Allergy. 1998, 53: 473-6.
• 8. DuBuske LM.Appropriate and inappropriate use of immunotherapy. Ann Allergy Asthma Immunol 2001, 87(1 Suppl 1): 56-67.
• 9. Karaayvaz M, Erel F, Caliskaner Z, Ozanguc N. Systemic reactions due to allergen immunotherapy J Investing Allergol Clin Immunol 1999, 9(1): 39-44.
• 10. Önefl Ü, Yaz›c›o¤lu M, Güler N, Yalç›n I, Salman N. Allerjen immunoterapisinde lokal ve sistemik yan etkiler. VI. Ulusal Allerji ve Klinik ‹mmunoloji Kongresi: PS 72, 1994.
• 11. Günefler Kendirli S, Y›lmaz M, Bingöl G, Alt›ntafl DU. Allerjen immunoterapisi uygulanan hastalarda görülen komplikasyonlar. VIII. Ulusal Allerji ve Klinik ‹mmunoloji Kongresi: PS 85, 1998.
• 12. Toubi E, Kessel A, Blant A, Golan TD Follow-up after systemic adverse reactions of immunotherapy. Allergy 1999, 54(6): 617-20.
• 13. Tinkelman DG, Cole WQ 3rd, Tunno J. Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol 1995, 95(1 Pt 1): 8-14.